

Pearce IP

Intellectual property specialists for the pharmaceutical and biopharmaceutical industries.
Providing IP services from early R&D to commercial launch, and beyond.
At Pearce IP our lawyers want to change the world. We work with life sciences organisations, creating and implementing Intellectual Property strategies supporting the timely development and launch of medicines. We help change the world, one patent at a time.

Legal Influencer

Q1 | 2026

Pearce IP

CONNECT WITH US

in

Following

Filter by Jurisdiction

Filter by work area

Articles

Events

Press Releases

Most Popular

Fresenius/SCD Settle US Biosimilar Aflibercept Dispute with Regeneron
Pearce IP, USA , 24 Feb 26

Pearce IP BioBlast® for the week ending 14 August 2026
Pearce IP, Australia, China, Malaysia..., 18 Aug 26

Pearce IP BioBlast® for the week ending 7 August 2026
Pearce IP, Australia, European Union, Netherlands..., 11 Aug 26

New Indication Alert: Opdivo®/Yervoy® Combo Approved in Japan for MSI-High CRC
Pearce IP, Japan , 25 Aug 25

Dutch Court Grants Preliminary Injunction Preventing Sale of Compounded Semaglutide Nasal Spray
Pearce IP, Netherlands , 05 Aug 26

Sandoz and Shanghai Henlius Enter US\$100.5M Strategic Collaboration for Up to 10 Biosimilars Including Cetuximab, Evolocumab and
Pearce IP, Australia , 17 Aug 26

Mabwell Inks Licensing Deal for Aflibercept Biosimilar in Philippines, Vietnam and Malaysia
Pearce IP, Malaysia, Philippines, Vietnam , 11 Aug 26

Bayer's Eylea® (Aflibercept) 8 mg Application Accepted for Review in China for Macular Oedma Following RVO
Pearce IP, China , 13 Aug 26

FDA approves Replimune's RP1 for Advanced Melanoma
Pearce IP, USA , 06 Aug 26

Samsung Bioepis Files First Korean Application for Biosimilar to MSD's Keytruda® (Pembrolizumab)
Pearce IP, South Korea , 10 Aug 26

FDA Grants Fast Track Designation for Celltrion's ADCs
Pearce IP, South Korea , 13 Aug 26

Samsung Bioepis Launches PFS Aflibercept Biosimilar in Europe
Pearce IP, European Union , 10 Aug 26

More

Author Leaderboard

Show: 7 days 30 days 90 days

1.

Naomi Pearce
Pearce IP

2.

Chantal Savage
Pearce IP

3.

Maliha Hoque
Pearce IP

4.

Sally Paterson
Pearce IP

5.

Helen Macpherson
Pearce IP

6.

Paul Johns
Pearce IP

7.

Donna Meredith
Pearce IP

8.

Dr. Mathew Lucas
Pearce IP

9.

Jacinta Flattery-O'Brien PhD
Pearce IP

10.

Julie Ballance
Pearce IP

Rankings in Lexology Index

Lexology Index identifies the foremost legal practitioners and consulting experts in business law based upon comprehensive, independent research. [Find out more](#)

2

ranked experts

2 experts at this firm are ranked in [Index - Australia & New Zealand 2025](#)

2 experts at this firm are ranked in [Index - IP 2026](#)

1 expert at this firm is ranked in [Index - Healthcare & Life Sciences 2026](#)

1 expert at this firm is ranked in [Index - Client Choice 2026](#)

View in-depth analytics

Search for an expert

Lexology Legal Influencers

Lexology's Legal Influencers programme recognises firms and authors that provide excellent content within a work area and region. [Find out more](#)

Legal Influencer: Pearce IP

Q1 | 2026 in Dispute resolution - Australasia

Q1 | 2026 in Healthcare and life sciences - Australasia

Q1 | 2026 in Healthcare and life sciences - Cross-border

Q4 | 2025 in Dispute resolution - Australasia

Q4 | 2025 in Healthcare and life sciences - Australasia

Q4 | 2025 in Healthcare and life sciences - Cross-border

Q3 | 2025 in Healthcare and life sciences - Australasia

Q3 | 2025 in Healthcare and life sciences - Europe

Q2 | 2025 in Healthcare and life sciences - Australasia

Q2 | 2025 in Healthcare and life sciences - Europe

Q2 | 2025 in Healthcare and life sciences - Cross-border

Q1 | 2025 in Healthcare and life sciences - Australasia

Q1 | 2025 in Healthcare and life sciences - Europe

Q1 | 2025 in Healthcare and life sciences - Cross-border

Q4 | 2024 in Healthcare and life sciences - Australasia

Q4 | 2024 in Healthcare and life sciences - Europe

Q4 | 2024 in Healthcare and life sciences - Cross-border

Q3 | 2024 in Healthcare and life sciences - Australasia

Q3 | 2024 in Healthcare and life sciences - Europe

Q3 | 2024 in Healthcare and life sciences - Cross-border

Q2 | 2024 in Healthcare and life sciences - Australasia

Q2 | 2024 in Healthcare and life sciences - Cross-border

Q1 | 2024 in Healthcare and life sciences - Australasia

Q1 | 2024 in Healthcare and life sciences - Cross-border

Q4 | 2023 in Healthcare and life sciences - Australasia

Q4 | 2023 in Healthcare and life sciences - Cross-border

Q3 | 2023 in Healthcare and life sciences - Australasia

Q3 | 2023 in Healthcare and life sciences - Cross-border

Q2 | 2023 in Healthcare and life sciences - Australasia

Q2 | 2023 in Healthcare and life sciences - Cross-border

Q1 | 2023 in Healthcare and life sciences - Cross-border

Q3 | 2022 in IP - Australasia

Q3 | 2022 in Healthcare and life sciences - Australasia

Q2 | 2022 in Healthcare and life sciences - Australasia

Q1 | 2021 in Healthcare and life sciences - Australasia

Q4 | 2020 in Healthcare and life sciences - Australasia

Less

Offices

Australia

New Zealand

Resources

Daily newsfeed

Panoramic

Research hubs

Learn

In-depth

Lexy Find

Scanner

Contracts & clauses

Lexology Index

Find an expert

Reports

Research methodology

Submissions

FAQ

Instruct Counsel

Client Choice 2025

More

Lexy AI

About us

Legal Influencers

Firms

Blog

Events

Popular

Lexology Academic

Lexology Talent Management

Legal

Terms of use

Cookies

Disclaimer

Privacy policy

Contact

Help centre

Contact

RSS feeds

Submissions

Login

Register

Search Lexology

Follow on X

Follow on LinkedIn

© Copyright 2026 LBR trading as Centelllic

CENTELLIC



Naomi Pearce

Pearce IP

LEXOLOGY INDEX
HIGHLY RECOMMENDED

- About
- Rankings
- Legal Influencers
- Publications
- Skills & Languages

Naomi is a market leading, strategic, commercially astute, patent lawyer, patent attorney and trade mark attorney, with over 25 years' experience, and a background in molecular biology/biochemistry.

Amongst other awards, Naomi is ranked in IAM Patent 1000, IAM Strategy 300, is a MIP "Patent Star", WIPR Leader, and a 2022 WIPR "Diversity Champion in IP". She is the 2022 Women in Business Law Asia Pacific "Patent Lawyer of the Year", 2022 Australasian Lawyer "Most Influential Lawyer" in the category of "changemaker", and the 2021 Lawyers Weekly Women In Law SME "Partner of the Year". Naomi is the founder of Pearce IP, which commenced in 2017 and won 2021 "IP Team of the Year" at the Australian Law Awards.

Underpinning Naomi's legal work is a deep understanding of life sciences industries, resulting from first-hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.

Naomi builds elegant market entry strategies which align with clients' commercial objectives, and are anchored with legal and technical excellence. Naomi manages AU patent litigations in the Australian Courts and excels in multi-jurisdictional litigations.

Naomi's industry focus is life s...

[Read full bio](#)

FEEDBACK FROM OUR RESEARCH

"Naomi is a highly strategic thinker and practitioner who thinks not only of local ramifications, but also global ones" "She brings a deep level of commercial insight to her stellar legal advice" "She is hugely knowledgeable on IP issues surrounding commercial aspects of preparing product launch and assessing risks involved"

- Contact me by email
- Visit firm website
- +61 (0) 2 9023 9988

Follow



Lexology Legal Influencer
Q3 | 2025

Rankings in Lexology Index

Client Choice

Category: Client Choice - IP - Patents Index Ranking: Highly Recommended

+ READ MORE

Australia & New Zealand

Category: Australia & New Zealand - IP - Patents Index Ranking: Recommended

Australia & New Zealand

Category: Australia & New Zealand - Life Sciences Index Ranking: Recommended

Healthcare & Life Sciences

Category: Healthcare & Life Sciences - Patent Litigation Index Ranking: Recommended

IP

Category: IP - Patents Index Ranking: Recommended

Legal Influencers

Q3 | 2025 in Dispute resolution - Australasia

Q1 | 2025 in Dispute resolution - Australasia

Q3 | 2024 in Healthcare and life sciences - Cross-border

[Show all](#)

Publications

Articles

16 Aug 2026

Pearce IP BioBlast® for the week ending 14 August 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending...

11 Aug 2026

Pearce IP BioBlast® for the week ending 7 August 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending...

04 Aug 2026

Pearce IP BioBlast® for the week ending 31 July 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending...

28 Jul 2026

Pearce IP BioBlast® for the week ending 24 July 2026

On 24 July 2026, Outlook Therapeutics announced that the FDA has approved ONS-5010/Lytenava™ (bevacizumab-vikg) for the treatment of neovascular...

21 Jul 2026

Pearce IP BioBlast® for the week ending 17 July 2026

Pearce IP provides weekly reports on global biosimilars activities in the Pearce IP BioBlast®. Significant biosimilar activities for the week ending...

View more

Skills

- Biopharmaceutical

Biosimilar

Gene therapy

Generic drug

Litigation

Patent infringement
- Patent term extension

Patents

Pharmaceuticals

Trademarks

Healthcare & Life Sciences

Intellectual Property
- Litigation

Patents

Trademarks

Contact Naomi Pearce

info@pearceiplaw
+61 (0) 2 9023 9988

Pearce IP

Level 3, 32 Martin Place
2000
Sydney, Australia

LEXOLOGY INDEX

Find out more about Lexology Index's research methodology and how you can get involved.

Resources

Daily newfeed
Panoramic
Research hubs
Learn
In-depth
Lexy Find
Scanner
Contracts & clauses

Lexology Index

Find an expert
Reports
Research methodology
Submissions
FAQ
Instruct Counsel
Client Choice 2025

More

Lexy AI
About us
Legal Influencers
Firms
Blog
Events
Popular
Lexology Academic
Lexology Talent Management

Legal

Terms of use
Cookies
Disclaimer
Privacy policy

Contact

Help centre
Contact
RSS feeds
Submissions

Search Lexology

Follow on X
Follow on LinkedIn



Helen Macpherson

Pearce IP

Follow



Lexology Legal Influencer
Q1 | 2026

View Biography

Rankings

IP

Category: IP - Copyright

Index Ranking: Recommended

Australia & New Zealand

Category: Australia & New Zealand - IP - Copyright

Index Ranking: Recommended

View less

Lexology Legal Influencers

Lexology Legal Influencers recognises legal industry leaders who have consistently provided users with valuable insights within a specific practice area and region.

- Q1 | 2026 in Dispute resolution - Australasia
- Q4 | 2025 in Dispute resolution - Australasia

See all

Find out more

Most popular

Most recent

91 articles

Zoetis Vaccine Patents' Last Stand

03 May 2024

Justice Rofe has delivered a further supplementary decision in the dispute between Boehringer Ingelheim Animal Health USA Inc (Boehringer) and Zoetis...

Healthcare & Life Sciences

Litigation

Patents

Australia

No Stay, No Delay: Federal Court Pushes Long-Running Litigation Forward Despite High Court Horizon

02 Jan 2025

Justice Burley has handed down a decision in a long-running dispute between Otsuka Pharmaceutical Co., Ltd (Otsuka) and Generic Health Pty Ltd...

Healthcare & Life Sciences

Litigation

Patents

Australia

Extended Release, Expeditious Rejection: Federal Court Invalidates Sun Pharma's Aripiprazole PTE

04 Jul 2025

On 5 February 2025, Justice Downes of the Federal Court of Australia delivered her decision in the dispute between Otsuka Japan and its licensees...

Litigation

Patents

Australia

Patent Opposition Fails to Block Patent Term Extension for COPD and Asthma Drug

20 Jun 2024

Glaxo Group Limited (Glaxo) applied for an extension of term of Australian Patent No. 2018282427 (AU2018282427) based on the product TRELEGY ELLIPTA...

Litigation

Patents

Australia

Don't Dig Your Own Hole - Broad Claims and a Deficient Disclosure Can Lead to Support, Sufficiency and Utility Issues

13 Jun 2024

CQMS has successfully opposed ESCO Group's (ESCO) patent application on the grounds of lack of support and sufficiency. In an interesting twist, the...

Litigation

Patents

Australia

View more

Resources

Daily newsfeed

Panoramic

Research hubs

Learn

In-depth

Lexy Find

Scanner

Contracts & clauses

Lexology Index

Find an expert

Reports

Research methodology

Submissions

FAQ

Instruct Counsel

Client Choice 2025

More

Lexy AI

About us

Legal Influencers

Firms

Blog

Events

Popular

Lexology Academic

Lexology Talent

Management

Legal

Terms of use

Cookies

Disclaimer

Privacy policy

Contact

Help centre

Contact

RSS feeds

Submissions

Search Lexology

Q

Follow on X

Follow on LinkedIn